tirzepatide cv outcomes trial Risk of major adverse cardiovascular events and stroke associated with treatment with GLP-1 or the dual GIP/GLP-1 receptor agonist for type 2 diabetes: A systematic review and meta-analysis Tirzepatide in SURPASS‑CVOT: Favorable Cardiovascular
Description
It contains tirzepatide , the same active ingredient found in the brand-name drugs Zepbound and Mounjaro
The synergy between these compounds addresses the primary limitation of GLP-1 medications: losing muscle alongside fat
Not necessarily
Is this product for human use
